UniCredit Bank GmbH Stock

Certificat

DE000HD453Z7

Market Closed - Deutsche Boerse AG 13:28:34 2024-05-31 EDT
35.1 EUR +0.40% Intraday chart for UniCredit Bank GmbH
Current month+8.84%
1 month+8.84%
Date Price Change
24-05-31 35.1 +0.40%
24-05-30 34.96 +0.60%
24-05-29 34.75 -0.43%
24-05-28 34.9 -0.63%
24-05-27 35.12 -.--%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 01:28 pm

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying ECKERT & ZIEGLER SE
IssuerLogo Issuer UniCredit UniCredit
WKN HD453Z
ISINDE000HD453Z7
Date issued 2024-03-26
Maturity 2025-03-21 (293 Days)
Parity 1 : 1
Emission price 32.51
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 35.32
Lowest since issue 30.01

Company Profile

Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Sector
-
More about the company

Ratings for Eckert & Ziegler SE

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eckert & Ziegler SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
45.66 EUR
Average target price
62.5 EUR
Spread / Average Target
+36.88%
Consensus